Celltrion Pharm Inc Total Assets
Celltrion Pharm Inc total assets. Based on the latest financial reports, Celltrion Pharm Inc (068760) holds total assets worth ₩745.80 Billion KRW (≈ $505.42 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Celltrion Pharm Inc for the company's overall valuation and market capitalisation.
Total Assets of Celltrion Pharm Inc (2011–2024)
Total assets of Celltrion Pharm Inc from 2011 to 2024. This chart illustrates how Celltrion Pharm Inc's total assets have evolved over time, based on quarterly financial data. See 068760 stock price and chart for real-time trading data and today's change.
Celltrion Pharm Inc - Asset Composition Analysis
Celltrion Pharm Inc Total Assets Breakdown (December 2024)
Celltrion Pharm Inc total assets breakdown as of December 2024. Celltrion Pharm Inc's total assets of ₩745.80 Billion consist of 58.5% current assets and 41.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩45.48 Billion | 6.8% |
| Accounts Receivable | ₩213.24 Billion | 31.9% |
| Inventory | ₩101.39 Billion | 15.2% |
| Property, Plant & Equipment | ₩222.70 Billion | 33.3% |
| Intangible Assets | ₩6.28 Billion | 0.9% |
| Goodwill | ₩32.91 Billion | 4.9% |
Asset Composition Trend (2011–2024)
This chart illustrates how Celltrion Pharm Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Celltrion Pharm Inc working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Celltrion Pharm Inc's current assets represent 58.5% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 6.8% of total assets in 2024, up from 1.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 31.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 33.3% of total assets.
Celltrion Pharm Inc Competitors by Total Assets
Key competitors of Celltrion Pharm Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Celltrion Pharm Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.61 | 1.58 | 1.25 |
| Quick Ratio | 1.16 | 1.06 | 0.95 |
| Cash Ratio | 0.00 | 0.12 | 0.00 |
| Working Capital | ₩176.86 Billion | ₩138.48 Billion | ₩46.03 Billion |
Celltrion Pharm Inc - Advanced Valuation Insights
This section examines the relationship between Celltrion Pharm Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.63 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | ₩669.46 Billion |
| Market Capitalization | $1.08 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Celltrion Pharm Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Celltrion Pharm Inc's assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Celltrion Pharm Inc (2011–2024)
The table below shows the annual total assets of Celltrion Pharm Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩669.46 Billion ≈ $453.69 Million |
+4.34% |
| 2023-12-31 | ₩641.64 Billion ≈ $434.83 Million |
+6.99% |
| 2022-12-31 | ₩599.72 Billion ≈ $406.42 Million |
-5.98% |
| 2021-12-31 | ₩637.88 Billion ≈ $432.29 Million |
+16.39% |
| 2020-12-31 | ₩548.07 Billion ≈ $371.42 Million |
+16.37% |
| 2019-12-31 | ₩470.98 Billion ≈ $319.18 Million |
+4.10% |
| 2018-12-31 | ₩452.44 Billion ≈ $306.61 Million |
-3.79% |
| 2017-12-31 | ₩470.27 Billion ≈ $318.69 Million |
-7.79% |
| 2016-12-31 | ₩510.02 Billion ≈ $345.63 Million |
+9.27% |
| 2015-12-31 | ₩466.77 Billion ≈ $316.32 Million |
+13.52% |
| 2014-12-31 | ₩411.16 Billion ≈ $278.64 Million |
+13.78% |
| 2013-12-31 | ₩361.35 Billion ≈ $244.88 Million |
+9.16% |
| 2012-12-31 | ₩331.04 Billion ≈ $224.34 Million |
+53.20% |
| 2011-12-31 | ₩216.08 Billion ≈ $146.43 Million |
-- |
About Celltrion Pharm Inc
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals a… Read more